The global hepatitis test solution/diagnosis market is estimated to account for USD 2.66 billion in 2018 and is projected to reach USD 3.37 billion by 2023, at a CAGR of 4.9%.

The high burden of hepatitis worldwide, increasing number of blood transfusions & donations, benefits offered by point of care instruments & kits, and initiatives taken by government and non-government organizations are the major factors driving this market.

Download Free Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=139802887

On the basis of end user, the market is segmented into hospitals & diagnostics labs, blood banks, and other end users. Hospitals & diagnostics labs segment is expected to grow at the highest CAGR during the forecast period. This can be attributed to the growing patient population, increase in Medicare reimbursement for clinical tests performed in hospitals, and the emergence of advanced diagnostic tests.

On the basis of technology, the hepatitis test solution/diagnosis market is segmented into rapid diagnostics test, INAAT, PCR, ELISA, and other technologies. RDT is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the low cost of this test type, its high analytical sensitivity, and its ability to detect all known 11 subtypes of HBsAg.

On the basis of disease type, the market is segmented into hepatitis B, hepatitis C, and other hepatitis disease. The hepatitis C segment is projected to grow at the highest CAGR during the forecast period. This growth is mainly attributed to the increasing incidence of HCV infections and limited vaccination coverage.

The market is segmented by geography into North America, Europe, Asia Pacific (APAC), and the Rest of the World (RoW). North America is expected to account for the largest share of the global hepatitis test solution/diagnosis market in 2018. This is mainly attributed to factors such as the developed healthcare systems in the US and Canada, rising adoption of advanced technologies, and the presence of a large number of leading national clinical laboratories.

The APAC region is expected to grow at the highest CAGR over the next five years. The growth of the hepatitis test solution/diagnosis market is fueled by the high burden of hepatitis infections, increased healthcare spending by a larger population base, modernization of healthcare infrastructure, and the rising penetration of cutting-edge clinical laboratory technologies (especially in rural areas).

Developing economies such as India, China, South Korea, Brazil, Turkey, and South Africa are expected to offer potential growth opportunities for the major players operating in the hepatitis test solution/diagnosis market. This can be attributed to the high disease prevalence, large patient pool, undiagnosed population, improving healthcare infrastructure, increasing disposable income, and growing medical tourism in these regions.